As Th2A cells are pathogenic for allergic diseases, relative monoclonal antibodies are widely used, such as IL-4 monoclonal antibody (Pitrakinra, Dupilumab) (95–97), IL-5 monoclonal antibody (Mepolizumab, Reslizumab, Benralizumab) (98), IL-9 monoclonal antibody (MEDI-528) (99), IL-13 monoclonal antibody (Lebrikizumab, Tralokinumab) (100, 101), IL-33 monoclonal antibody (Etokimab, AMG 282) (102, 103), TSLP monoclonal antibody (Tezepelumab) (104), and IgE monoclonal antibody (Omalizumab, Ligelizumab) (105, 106). Here, IL33 is linked to allergic disease.